HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Eribulin mesylate in heavily pretreated metastatic breast cancer patients: current practice in an Italian community hospital.

AbstractAIM:
The aim of this study is to report on the activity and safety of eribulin mesylate in a representative number of pretreated metastatic breast cancer (MBC) patients in current practice. Eribulin mesylate, a new microtubule inhibitor, is approved as monotherapy for the treatment of patients with locally advanced breast cancer or MBC who have progressed after at least two chemotherapeutic regimens for advanced disease.
PATIENTS & METHODS:
From February to October 2012, 27 MBC patients, previously treated with anthracyclines and taxanes, were treated with 1.4 mg/m(2) intravenous infusion of eribulin mesylate at a community hospital.
RESULTS:
Eight (30%) patients achieved partial response, one achieved complete response and three achieved stable disease. Median duration of response was 2.5 months (95% CI: 1.6-5.7; range: 1.3-5.7). Median overall survival was 8 months (95% CI: 6.1-9.7; range: 0.6-9.9). Reported adverse events were grade 1-2 asthenia (83%), peripheral sensory neuropathy (48%), nausea (37%) and neutropenia (30%).
CONCLUSION:
Our retrospective analysis of a clinical practice experience supports the evidence that eribulin mesylate has clinical activity and provides acceptable benefit to heavily pretreated MBC.
AuthorsPaola Poletti, Valentina Ghilardi, Luca Livraghi, Laura Milesi, Elena Rota Caremoli, Carlo Tondini
JournalFuture oncology (London, England) (Future Oncol) Vol. 10 Issue 2 Pg. 233-9 (Feb 2014) ISSN: 1744-8301 [Electronic] England
PMID24490609 (Publication Type: Journal Article)
Chemical References
  • Antineoplastic Agents
  • Furans
  • Ketones
  • eribulin
Topics
  • Adult
  • Aged
  • Antineoplastic Agents (administration & dosage, adverse effects, therapeutic use)
  • Breast Neoplasms (mortality, pathology, therapy)
  • Female
  • Furans (administration & dosage, adverse effects, therapeutic use)
  • Hospitals, Community
  • Humans
  • Italy
  • Ketones (administration & dosage, adverse effects, therapeutic use)
  • Middle Aged
  • Neoplasm Metastasis
  • Retreatment
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: